Abbott Sees Absorb Bioresorbable Implant As Stent Market Game Changer

Abbott will commence a 2,000-patient clinical trial by year end to support U.S. approval of its Absorb drug-eluting bioresorbable vascular scaffold as an alternative to conventional coronary stents following an initial European debut.